UNITED STATI	ES PATENT AND TRADEMARK OFFICE
BEFORE THE	PATENT TRIAL AND APPEAL BOARD
AQUI	ESTIVE THERAPEUTICS, INC.
	Petitioner
	v.
	NEURELIS, INC.
_	Patent Owner
	IPR2019-00451
	U.S. Patent No. 9,763,876






TABLE OF CONTENTS

I.	BASIS FOR OPINION	2
II.	RELEVANT CONSIDERATIONS	13
A.	POSA	18
1.	Ethanol Versus Dehydrated Ethanol	20
III.	QUALIFICATIONS AND BACKGROUND	22
IV.	GROUNDS FOR INVALIDATING THE '876 PATENT CLAIMS	26
V.	THE HISTORY OF INTRANASAL BENZODIAZEPINE DELIVERY	Y29
A.	Summary	29
B.	Introduction	30
C.	Nasal Anatomy As Related to Intranasal Drug Delivery	32
VI.	COMMERCIAL SUCCESS AND LONG-FELT NEED IN THE DESI	IGN
OF N	ASAL PRODUCTS FOR SYSTEMIC DRUG ADMINISTRATION	
INCL	UDES TECHNICAL CONSIDERATIONS AS WELL AS MARKETIN	G
CONS	SIDERATIONS	36
A.	Exclusion of Market Considerations	36



B.	Patent Owner's Expert Testified That he was Unaware of the Composition
of Pat	ent Owner's Intranasal Diazepam Spray, Valtoco, and He Could Not Answer
Whetl	her Valtoco Satisfied any Long-Felt Need37
C.	Commercial Success Factors – Formulation and Commercial
Consi	derations40
1.	Product Design Considerations42
2.	Pharmacokinetics And Pharmacodynamics Of Nasal Benzodiazepines In
Healtl	hy Volunteers49
D.	Prior Art Experience With Intranasal Delivery Of Benzodiazepines For
Treati	ment Of Seizures Prior To 200953
VII.	THE PATHWAY TO FORMULATING THE SOLUTION58
1.	There Were Many Nasal Delivery Systems And Many Non-Technical
Proble	ems To Their Commercialization61
2.	Background In The Intranasal Art72
VIII.	GWOZDZ, MEEZAN'962 and CARTT'784 MAKE ALL THE CLAIMS
OF T	HE '876 PATENT OBVIOUS84
A.	Gwozdz (Exhibit 1014)85



1.	A POSA Would Have Used Gwozdz' Disclosure of Ternary Co-Solvent
Systen	s Such as Tocopherol+ Ethanol+Benzyl Alcohol, and Gwozdz' Disclosure
is Not	Limited to Administration to One Nostril86
	(a) A POSA Would Expect that a Ternary Co-Solvent System
	(Tocopherol+Ethanol+Benzyl Alcohol) Could Solubilize More Diazepam
	Than a Binary Co-Solvent System (Tocopherol+Ethanol)86
	(b) Gwozdz' Ternary Co-Solvent Diazepam Solution in a Reduced
	Concentration Can be Administered to Both Nostrils to Deliver the Same
	Amount of Diazepam and Avoid Possibility of Precipitating Out91
2.	The Combination of Ethanol and Benzyl Alcohol and Diazepam for Use in
Treation	g Seizures in Humans was Well Known92
B.	A POSA HAD THE MOTIVATION TO COMBINE THE TEACHINGS
OF GV	OZDZ, MEEZAN'962 AND CARTT'78498
1.	Contrary to Patent Owner's argument, a POSA would not be deterred from
applyi	ng Meezan'962's teaching of the use of alkyl glycosides in connection with
non-ac	ueous solutions99
2.	Contrary to Patent Owner's argument, a POSA would not be deterred from
applyi	ng the teachings of Cartt'784 to the disclosures of Gwozdz. Rather, the
POSA	would be motivated to combine the two references100



IX.	The '558 Provisional Application's (Exhibit 1008) incorporation by
referer	nce of the Sigma Catalogue (Exhibit 2006) does not convey to a POSA either
a direc	ted disclosure of alkyl glycosides as absorption enhancer or even that the
invent	ors knew that alkyl glycosides would necessarily work as such103
X.	THERE ARE NO UNEXPECTED RESULTS OR CRITICALITY
ASSO	CIATED WITH ANY OF THE RECITED ALCOHOL RANGES OR
AMOU	JNTS108
A.	A POSA Would Have Known that Tocopherols Contribute to Increased
Bioava	nilability111
B.	A POSA Would Have Expected Solutions to Have Higher Bioavailabilities
Than S	Suspensions112
C.	Diazepam is 100% Bioavailable For Nasal and Oral Absorption113
D.	The Table 11-3 data for the solution is not evidence of any criticality
associa	ated with the recited claim ranges for ethanol and benzyl alcohol117
1.	Nasally-Administered Diazepam's 100% Nas-Oral Bioavailability120
2.	No Data Regarding Bioavailability of Solutions Having Benzyl Alcohol
and Et	hanol Other Than in Table 11-3 (10.5% benzyl alcohol and 18.07% ethanol
(dehyc	Irated))121



DOCKET A L A R M

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

